Patricia Kingori, Professor of Global Health Ethics at Oxford Population Health\u2019s Ethox Centre, and The Oxford Research Centre in the Humanities (TORCH), kick off April Fakes Day 2025 with a week-long cultural programme of exhibits and events that expose history\u2019s fakers, fraudsters and those who fool.
The climate crisis is reshaping every aspect of our world, including health care. While health systems are designed to protect and improve lives, they also contribute significantly to environmental degradation through greenhouse gas emissions, waste and pollution, and unsustainable supply chains. How can we transform health care to operate within planetary limits while maintaining fairness, equity, and optimal patient outcomes?
Cancer Research UK and partners have today committed \u00a35.5m in funding to form a world-leading research team tasked with making personalised medicine a reality for people with bowel cancer. The team will be co-led by Professor Simon Leedham from the Nuffield Department of Medicine at the University of Oxford.
New research from the Kennedy Institute has revealed how two important proteins, TBK1 and IKKe, play a crucial role in preventing premature cell death, which can lead to serious inflammation in the body. The findings are particularly relevant for people with a mutation in the TBK1 gene who often develop multiorgan inflammation caused by excessive cell death even in the absence of any infection.
An international team, led the Nuffield Department of Primary Care Health Sciences, is calling for a fundamental shift in how we conduct health research to better serve our real-world health and care needs.
The University of Oxford in partnership with the Coler Lab at Seattle Children\u2019s Research Institute (SCRI) has begun a new clinical trial called TB045, which aims to test tuberculosis (TB) vaccine safety and the host immune response in a first-in-human aerosol mycobacterial challenge infection model with healthy adult volunteers.
A study led by researchers from Oxford Population Health has found that daily physical activity is linked to a lower risk of cancer. The number of steps taken daily may be more important for cancer risk than the intensity of activity.
Ranking 11th globally in antibiotic use, Vietnam faces a serious risk of drug resistance, and could be \u2018running out of treatment options due to antibiotic resistance\u2019.
People could get the right help for the diseases that can cause dementia sooner following the announcement today of a \u00a32 million injection of funding from the government to help spot these earlier.
An international collaboration, initiated by the Jackson Group at the MRC Weatherall Institute of Molecular Medicine, has uncovered new information that could help in the development of drugs to block conditions such as autoimmunity and inflammation.
University of Oxford researcher, Katherine Vallis, has been awarded new funding from the MRC to launch a project on the use of cell-permeant antibodies for the treatment of acute leukaemia. The funding will allow Prof. Vallis and her team to generate in vivo data on the use of cell-penetrating peptides (CPPs) for cancer applications, a crucial step towards clinical translation.
Monday 24 March is World Tuberculosis Day. Along with its international collaborators, Oxford remains at the forefront of research to develop new vaccines to protect against this devastating disease.
Researchers from around the UK, led by the University of Oxford, have found that a new way of performing prostate biopsies is better at diagnosing prostate cancer, but takes longer to perform and is more painful for patients.
A collaboration between the Drakesmith and Higgs Groups at the Medical Research Council Weatherall Institute of Molecular Medicine (MRC WIMM) has identified an ancient connection between metabolic and transcriptional control of erythropoiesis.
Genomic testing and targeted therapies for patients with advanced cancer could improve survival rates by up to 40%, according to researchers at the Norfolk and Norwich University Hospital, University of Adelaide and University of Oxford.
Co-led by PSI Director Professor Sir Peter Horby, the RECOVERY trial was defined \"one of the most well-known studies supported by the NIHR with clear national and global impact\u201d.
![\"Purple](\"https://www.medsci.ox.ac.uk/news/oxford-unmasks-the-fraudsters-behind-the-forgeries-for-april-fakes-day-2025/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n